Integer begins strategic review for possible sale or merger

9 articles · Updated · MarketWatch · Apr 30

Board chair Pamela Bailey said strong interest prompted the move as Integer cut 2026 sales guidance to $1.81 billion-$1.84 billion and adjusted EPS to $5.83-$6.40.
The medical-device company cited headwinds in three products, whose customer adoption has lagged management expectations, and said there is no deadline or assurance the review will produce a deal.
First-quarter revenue was roughly flat at $439.6 million, while Integer swung to a $16.5 million profit, or 48 cents a share, from a $22.5 million loss a year earlier.

Amidst strong buyout interest, why is medical device giant Integer suddenly lowering its financial outlook and facing product headwinds?

Is an activist investor's new stake and a board shakeup forcing Integer's hand into a potential billion-dollar sale?